Randomized phase III study of 2 cisplatin-based chemoradiation regimens in locally advanced head and neck squamous cell carcinoma: impact of changing disease epidemiology on contemporary trial design.

@article{Rodriguez2015RandomizedPI,
  title={Randomized phase III study of 2 cisplatin-based chemoradiation regimens in locally advanced head and neck squamous cell carcinoma: impact of changing disease epidemiology on contemporary trial design.},
  author={Cristina P Rodriguez and David Adelstein and Lisa A. Rybicki and Panayiotis S Savvides and Jerrold P. Saxton and Shlomo A. Koyfman and John F. Greskovich and Min Li Yao and Joseph Scharpf and Pierre N Lavertu and Benjamin G. Wood and Brian B. Burkey and Robert R. Lorenz and Rod P Rezaee and Chad A. Zender and Denise I. Ives},
  journal={Head & neck},
  year={2015},
  volume={37 11},
  pages={1583-9}
}
BACKGROUND Chemoradiotherapy results in excellent outcomes in locally advanced head and neck squamous cell carcinoma (HNSCC). This trial compared 2 chemoradiotherapy regimens. METHODS Patients with locally advanced HNSCC were treated with radiation (70-74.4 Gy), and randomized to arm A: cisplatin 100 mg/m(2) on radiotherapy (RT) days 1, 22, and 43, or arm B: cisplatin (20 mg/m(2) /day) and 5-fluorouracil (5-FU; 1000 mg/m(2) /day) continuous 96-hour infusions on RT weeks 1 and 4. The primary… CONTINUE READING